OverviewSuggest Edit

ESSA Pharma is a pharmaceutical company focused on developing therapies for the treatment of prostate cancer. It offers anitens that block a target on the androgen receptor (AR), the N-terminal domain.
TypePublic
Founded2009
HQVancouver, CA
Websiteessapharma.com
Overall CultureB

Latest Updates

Employees (est.) (Sept 2020)25
Share Price (May 2021)$30
Cybersecurity ratingBMore

Key People/Management at ESSA Pharma

Richard Glickman

Richard Glickman

Chairman of the Board
David R. Parkinson

David R. Parkinson

President, Chief Executive Officer & Director
Peter Virsik

Peter Virsik

Chief Operating Officer, Executive Vice President
Scott Requadt

Scott Requadt

Director
Alessandra Cesano

Alessandra Cesano

Chief Medical Officer
David S. Wood

David S. Wood

Chief Financial Officer
Show more

ESSA Pharma Office Locations

ESSA Pharma has offices in Vancouver, Houston and South San Francisco
Vancouver, CA (HQ)
999 W Broadway #720
Houston, TX, US
700 Milam St #1300
South San Francisco, CA, US
400 Oyster Point Blvd #520
Show all (3)

ESSA Pharma Financials and Metrics

ESSA Pharma Revenue

USD

Net income (Q1, 2021)

(6.5m)

Market capitalization (3-May-2021)

1.2b

Closing stock price (3-May-2021)

30.0

Cash (31-Dec-2020)

52.5m

EV

1.1b
ESSA Pharma's current market capitalization is $1.2 b.
Annual
USDFY, 2018FY, 2019FY, 2020

General and administrative expense

5.9m5.5m11.4m

R&D expense

4.9m6.7m12.1m

Operating expense total

11.7m12.8m24.1m

Interest income

42.7k26.3k559.7k
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

General and administrative expense

1.2m1.8m1.2m2.1m4.9m2.2m2.2m

R&D expense

1.3m1.5m2.0m2.6m4.6m2.7m4.5m

Operating expense total

2.7m3.4m3.3m4.9m9.6m5.1m6.7m

Interest income

101.0k205.6k172.3k35.7k
Annual
USDFY, 2018FY, 2019FY, 2020

Cash

14.8m53.3m56.3m

Accounts Receivable

297.3k360.8k309.5k

Prepaid Expenses

470.2k615.5k1.6m

Current Assets

15.6m54.3m80.3m
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

12.2m8.6m4.9m45.9m39.9m36.5m52.5m

Accounts Receivable

247.6k274.9k350.1k349.5k348.6k231.2k

Prepaid Expenses

377.2k172.8k471.8k955.9k913.0k1.1m

Current Assets

12.8m5.3m46.8m41.2m37.7m75.9m
Annual
USDFY, 2018FY, 2019FY, 2020

Net Income

(11.6m)(10.4m)(23.4m)

Depreciation and Amortization

34.5k18.3k110.3k

Accounts Payable

(1.1m)(1.0m)(46.4k)

Cash From Operating Activities

(10.2m)(12.2m)(17.0m)
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Net Income

(2.7m)(6.1m)(9.4m)(4.6m)(14.0m)(18.9m)(6.5m)

Depreciation and Amortization

4.6k9.1k13.7k32.2k64.3k96.5k27.6k

Accounts Payable

213.8k252.3k617.0k(163.0k)92.1k(83.2k)867.8k

Cash From Operating Activities

(1.9m)(4.6m)(7.1m)(3.4m)(9.3m)(12.6m)(3.9m)
USDFY, 2018

Debt/Equity

0.7 x

Debt/Assets

0.4 x

Financial Leverage

1.8 x
Show all financial metrics

ESSA Pharma Cybersecurity Score

Cybersecurity ratingPremium dataset

B

88/100

SecurityScorecard logo

ESSA Pharma Online and Social Media Presence

Embed Graph

ESSA Pharma Company Culture

  • Overall Culture

    B

    81/100

  • CEO Rating

    A-

    80/100

  • Compensation

    A+

    100/100

Learn more on Comparably

ESSA Pharma News and Updates

ESSA Pharma Presents Preclinical Data Supporting the Therapeutic Potential of EPI-7386 at the 2021 American Association of Cancer Research (AACR) Annual Meeting

HOUSTON, Texas and VANCOUVER, Canada, April 10, 2021 /PRNewswire/ -- ESSA Pharma Inc. ("ESSA" or the "Company") (Nasdaq: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today presented new preclinical data on...

ESSa Pharma Announces Exercise of Option in Connection With Recently Completed $130 Million Financing

ESSA Pharma Inc. (“ESSA”, or the “Company”) (Nasdaq: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the underwriters have exercised their option (the “Option”) to purchase an additional 724,637 common sh…

ESSA Pharma to Present at Upcoming March Investor Conferences

ESSA Pharma Inc. (“ESSA”, or the “Company”) (NASDAQ:EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that David R. Parkinson, President and Chief Executive Officer of ESSA Pharma, will be presenting and hosting…

ESSA Pharma Inc. Reports Results of Annual General and Special Meeting of Shareholders

ESSA Pharma Inc. (“ESSA” or the “Company”) (NASDAQ: EPIX, TSX-V: EPI), a clinical stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce the results of the votes on matters considered at its Annual General Meeting of Shareholde…

ESSA Pharma Frequently Asked Questions

  • When was ESSA Pharma founded?

    ESSA Pharma was founded in 2009.

  • Who are ESSA Pharma key executives?

    ESSA Pharma's key executives are Richard Glickman, David R. Parkinson and Peter Virsik.

  • How many employees does ESSA Pharma have?

    ESSA Pharma has 25 employees.

  • Who are ESSA Pharma competitors?

    Competitors of ESSA Pharma include MEI Pharma, Candel Therapeutics and Urogen Pharma.

  • Where is ESSA Pharma headquarters?

    ESSA Pharma headquarters is located at 999 W Broadway #720, Vancouver.

  • Where are ESSA Pharma offices?

    ESSA Pharma has offices in Vancouver, Houston and South San Francisco.

  • How many offices does ESSA Pharma have?

    ESSA Pharma has 3 offices.